Your Health, We Care
Upadacitinib is a reversible and orally selective JAK1 inhibitor developed and produced by AbbVie in the United States. It has shown significant efficacy and broad application prospects in the treatment of various immune-mediated diseases.
Upadacitinib has been approved for the treatment of various immune-mediated diseases, including rheumatoid arthritis (RA), atopic dermatitis (AD), psoriatic arthritis (PsA), etc. With the continuous development of biotechnology and the emergence of innovative drugs, Upadacitinib is expected to become one of the important drugs for treating immune-mediated diseases in the future.
